zanamivir

Zanamivir is an antiviral medication belonging to the class of neuraminidase inhibitors. It is primarily used for the treatment and prevention of influenza A and B infections. Zanamivir works by inhibiting the activity of viral neuraminidase, an enzyme essential for the release of new influenza virus particles from infected cells, thereby limiting the spread of infection within the body. The drug is administered via oral inhalation and must be started within 2 days of symptom onset to be effective. Zanamivir was developed based on structural insights into viral neuraminidase and was designed to closely mimic its natural substrate, reducing potential for resistance development[1][2][3][6]. The primary indication is uncomplicated acute illness due to influenza A or B in adults and children (age thresholds may vary by region), as well as prophylaxis in individuals exposed to influenza[1][2][3].

Brand names

Relenza

Other names

zanamivir